Cue Biopharma Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| For the three months ended June 30, 2024 and 2023: | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional · AccumulatedOther · Total | ||||||
| Shares | ParValue | Paid-inCapital | ComprehensiveIncome (Loss) | AccumulatedDeficit | Stockholders’Equity | |
| Balance, March 31, 2023 | 43,178,150 | $43 | $318,578 | $(39) | $(263,565) | $55,017 |
| Issuance of common stock from ATM offering, net of sales agent commission and fees | 536,264 | 1 | 2,015 | — | — | 2,016 |
| Stock-based compensation | — | — | 2,037 | — | — | 2,037 |
| Exercise of stock options | 30,000 | — | 85 | — | — | 85 |
| Unrealized gain from available-for-sale securities | — | — | — | 34 | — | 34 |
| Net loss | — | — | — | — | (13,185) | (13,185) |
| Balance, June 30, 2023 | 43,744,414 | $44 | $322,715 | $(5) | $(276,750) | $46,004 |
| Balance, March 31, 2024 | 48,643,316 | $48 | $343,527 | $— | $(313,537) | $30,038 |
| Stock-based compensation | — | — | 1,755 | — | — | 1,755 |
| Net loss | — | — | — | — | (10,171) | (10,171) |
| Balance, June 30, 2024 | 48,643,316 | $48 | $345,282 | $— | $(323,708) | $21,622 |
| For the six months ended June 30, 2024 and 2023: | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional · AccumulatedOther · Total | ||||||
| Shares | ParValue | Paid-inCapital | ComprehensiveIncome (Loss) | AccumulatedDeficit | Stockholders’Equity | |
| Balance, December 31, 2022 | 43,042,548 | $43 | $316,192 | $(96) | $(250,456) | $65,683 |
| Issuance of common stock from ATM offering, net of sales agent commission and fees | 536,264 | 1 | 2,015 | — | — | 2,016 |
| Stock-based compensation | — | — | 4,035 | — | — | 4,035 |
| Exercise of stock options | 165,602 | — | 473 | — | — | 473 |
| Unrealized gain from available-for-sale securities | — | — | — | 91 | — | 91 |
| Net loss | — | — | — | — | (26,294) | (26,294) |
| Balance, June 30, 2023 | 43,744,414 | $44 | $322,715 | $(5) | $(276,750) | $46,004 |
| Balance, December 31, 2023 | 47,215,116 | $47 | $338,228 | $— | $(301,190) | $37,085 |
| Issuance of common stock from ATM offering, net of sales agent commission and fees | 1,428,200 | 1 | 3,353 | — | — | 3,354 |
| Stock-based compensation | — | — | 3,701 | — | — | 3,701 |
| Net loss | — | — | — | — | (22,518) | (22,518) |
| Balance, June 30, 2024 | 48,643,316 | $48 | $345,282 | $— | $(323,708) | $21,622 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.